Alzheimer's Disease
- Home
- Alzheimer's Disease
Alzheimer’s Disease
The United States spent $343 billion in 2023 alone to combat dementia, including Alzheimer’s disease. Alzheimer’s disease is currently the sixth most common cause of mortality in the US for people of all ages, affecting over six million people.
FDA has approved a Phase IIa protocol to evaluate the safety, tolerability, and initial effectiveness of a single intravenous dose of allogeneic human mesenchymal stem cells in subjects with mild to moderate dementia caused by Alzheimer’s disease. SanoStem is keen on finding partners to advance this exciting study. Initial case reports have shown safety and preliminary efficacy.
From Alzheimer’s Disease Research.
Alzheimer’s Disease
The United States spent $236 billion in 2016 alone to combat dementia, including Alzheimer’s disease. Alzheimer’s disease is currently the sixth most common cause of mortality in the US for people of all ages, affecting over five million people.
In order to evaluate the safety, tolerability, and initial effectiveness of a single intravenous dose of allogeneic human mesenchymal stem cells in subjects with mild to moderate dementia caused by Alzheimer’s disease, Sanostem is undertaking a Phase IIa multicenter, randomized, single blind, placebo-controlled, crossover study.
From “Healthy Aging: Alzheimer’s Disease,” released in March 2015 by the Centers for Disease Control and Prevention.
